An #immunotherapy company focused on developing products for #cancer and #infectiousdiseases Vedantra Pharmaceuticals Inc. (spinout from MIT), is developing nanoparticle vaccines that are designed to generate a more potent antibody and T cell response than traditional subunit vaccines.
Vedantra Pharmaceuticals, Inc.
In Mar 2017, Vedantra signed a joint collaboration to explore cancer vaccine research with Neon Therapeutics. Under the terms, the two companies will contribute their respective expertise non-exclusively to explore the potential benefits of combining Vedantras albumin-binding, lymph node targeting amphiphile technology with Neons neoantigen vaccine research.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/vedantra-pharmaceuticals-inc.” connections=”true” suffix=””]
Vedantra subunit vaccine technology comprised of highly structured lipid nano-particles, that delivers antigens subunit and provides durable long lasting antibody and CTL responses. It co-packed antigens and molecular adjuvants, and have enhanced stability compare to liposomes due to high cross-linking.
In 2012, Vedantra received $3.3 Mn in equity funding from Access Bridge Gap Ventures.